29 Apr

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedInPrint me


MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC’ or ‘the Company’), a European based ‘Seed to Medicine’ bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce significant new research results that supports and directs novel cannabinoid formulations in the positive treatment of glioblastoma, the most aggressive and so far, therapeutically resistant primary brain tumour.

This research has, and continues to be, conducted in collaboration with the National Institute of Biology (‘NIB’) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia. The updated research, which is another considerable scientific breakthrough for the Company, continues to support the use of applying cannabinoid compounds against cancerous cells.

The MGC Pharma – NIB Second Reporting Study research (‘the Study’) recently submitted for publication by NIB has introduced the use of CBG (cannabigerol) to treat glioblastoma. This second report by NIB can be found on the Company’s website.

Key Highlights
• The Study os conducted by the National Institute of Biology (NIB) and University Medical Centre in Ljubljana, Slovenia with MGC Pharma’s R&D Division.

• Research collaboration is part of MGC Pharma's strategy of partnering with leading research institutions to examine opportunities to develop new pharma products based on proven cannabinoid formulations in pre-and clinical studies.

The objective of the research is to develop formulations to define the protocols for the treatment of high-grade brain tumours, i.e. glioblastoma with cannabinoids.

Significant new research results from NIB support and direct novel cannabinoid formulations in the treatment of glioblastoma.

• The Study has introduced the use of CBG (cannabigerol)–an additional non-intoxicating cannabinoid as anti-cancer agent. CBG, so far less investigated naturally occurring phyto-cannabinoid is enriched in younger cannabis plants with promising therapeutic characteristics.

Significantly new perspective from cannabinoids’ receptors study in glioblastoma also suggests that selective receptors, like CBR1 gene may be applied in clinical use as biomarker for glioblastoma progression and potential targets for new drugs, based on synthetic ligands of cannabinoid receptors.

Glioblastoma Stem Cells

• MGC Pharma/NIB research shows Canabigerol -CBG killing affects – APOPTOSIS on GLIOBLASTOMA STEM CELLS – RIGHT LEFT, which tend to be extremely resistant to irradiation and chemotherapy treatments (Figure 1).